DekaBank Deutsche Girozentrale’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,300	Closed	-$1.54M	–	1342
2023 Q1	$1.54M	Hold	14,300	–	–	﹤0.01%	776
2022 Q4	$1.57M	Hold	14,300	–	–	﹤0.01%	777
2022 Q3	$832K	Hold	14,300	–	–	﹤0.01%	919
2022 Q2	$398K	Hold	14,300	–	–	﹤0.01%	1062
2022 Q1	$537K	Buy	14,300 +1,300	+10%	+$51.4K	﹤0.01%	1048
2021 Q4	$489K	Buy	+13,000	New	+$407K	﹤0.01%	1100

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

DekaBank Deutsche Girozentrale's RXDX Position: Q2 2023 in Review

DekaBank Deutsche Girozentrale sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 14,300 shares — an estimated $1.54M sold.

DekaBank Deutsche Girozentrale first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $1.57M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

DekaBank Deutsche Girozentrale reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 14,300 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.54M.
DekaBank Deutsche Girozentrale first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
DekaBank Deutsche Girozentrale's Prometheus Biosciences, Inc. Common Stock position peaked at $1.57M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2023, filed 25 Jul 2023.